

Carcinoma In Situ

[View the current Carcinoma In Situ InDepth page on BioPortfolio.com](http://www.bioportfolio.com/indepth/Carcinoma_In_Situ.html) (PDF)

(http://www.bioportfolio.com/indepth/Carcinoma_In_Situ.html) - Regularly Updated.

Recent Publications on Carcinoma In Situ:



- [Reflectance Confocal Microscopy for Noninvasive Monitoring of Therapy and Detection of Subclinical Actinic Keratoses.](#)
*Background: Actinic keratoses (AK) represent cutaneous carcinoma in situ...*13th November, 2009
Skin Cancer Center Charite, Department of Dermatology, Charite University- Dermatology. 2009 Nov 11. ([DOI Direct Link](#))
- [Esophageal squamous papillomatosis with dysplasia. Is there a role of balloon-based radiofrequency ablation therapy?](#)
*Esophageal squamous papillomatosis (ESP) is a rare condition, occurring in...*12th November, 2009
Department of Gastroenterology, Dayton VA Medical Center, Wright State- Acta Gastroenterol Belg. 2009 Jul-Sep;72(3):373-6.
- [A unique proteolytic fragment of alpha1-antitrypsin is elevated in ductal fluid of breast cancer patient.](#)
*By comparison of mass spectra from a small cohort of nipple aspiration...*11th November, 2009
Department of Pathology, Johns Hopkins Medical Institutions, Baltimore,- Breast Cancer Res Treat. 2009 Nov 10. ([DOI Direct Link](#))
- [High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast.](#)
*Papillary lesions of the breast have an uncertain relationship to the...*10th November, 2009
Knight Cancer Institute, Oregon Health & Science University, Portland, OR,- Mod Pathol. 2009 Nov 6. ([DOI Direct Link](#))
- [MRI for the size assessment of pure ductal carcinoma in situ \(DCIS\): A prospective study of 33 patients.](#)
*OBJECTIVE: To determine whether MRI assesses the size of ductal carcinomas...*10th November, 2009
Department of Medical Imaging, Centre Antoine Lacassagne, 33 route de- Eur J Radiol. 2009 Nov 5. ([DOI Direct Link](#))
- [Might the widespread use of statin drugs explain the increase in prevalence of breast carcinoma in situ?](#)
*OBJECTIVE: To determine whether MRI assesses the size of ductal carcinomas...*10th November, 2009
Fountain Medical Court, 9410 Fountain Medical Court, Suite A-200, Bonita- Med Hypotheses. 2009 Nov 4. ([DOI Direct Link](#))
- [On the possibility of time-lapse ultrahigh-resolution optical coherence tomography for bladder cancer grading.](#)
*It has been recently demonstrated that the cellular details of bladder...*10th November, 2009
- J Biomed Opt. 2009 Sep-Oct;14(5):050502. ([DOI Direct Link](#))
- [Risk of carcinoma after subsequent excision of benign papilloma initially diagnosed with an ultrasound](#)

[\(US\)-guided 14-gauge core needle biopsy: a prospective observational study.](#)

*OBJECTIVE: To prospectively determine the upgrade rate following surgery...*6th November, 2009
Department of Radiology and Clinical Research Institute, Seoul National- Eur Radiol. 2009 Nov 5. ([DOI Direct Link](#))

- [Immunohistochemical Study of Matrix Metalloproteinase 9 and Tissue Inhibitor of Matrix Metalloproteinase 1 in Benign and Malignant Breast Tissue - Strong Expression in Intraductal Carcinomas of the Breast.](#)

*Objective: Matrix metalloproteinases (MMPs) are involved in carcinogenesis...*6th November, 2009
Department of Oncology and Radiotherapy, University Hospital of Oulu,- Tumour Biol. 2009 Oct 31;30(5):257-264. ([DOI Direct Link](#))

- [A quantitative theoretical model for the development of malignancy in ductal carcinoma in situ.](#)

*Mathematical models and clinical observations have demonstrated that...*6th November, 2009
Centro Infantil Boldrini, Campinas, SP 13083-210, Brazil.- J Theor Biol. 2009 Oct 31. ([DOI Direct Link](#))

- [Apocrine ductal carcinoma in situ involving a sclerosing lesion with adenosis: report of a case.](#)

*Apocrine metaplasia is a ubiquitous component of the mammary fibrocystic...*6th November, 2009
Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA.- Arch Pathol Lab Med. 2009 Nov;133(11):1817-21.

- [MRI versus ultrasonography and mammography for preoperative assessment of breast cancer.](#)

*Mammography and ultrasonography are traditional for preoperative...*5th November, 2009
John Wayne Cancer Institute at Saint John's Health Center, Santa Monica,- Am Surg. 2009 Oct;75(10):970-5.

- [Substance P and NK-1R expression in oral precancerous epithelium.](#)

*The objectives of this study were to investigate the presence and...*4th November, 2009
Facultad de Odontologia,- Oncol Rep. 2009 Dec;22(6):1325-31.

- [\[Squamous cell carcinoma and potentially malignant disorders of the oral mucosa.\]](#)

*Squamous cell carcinoma is the most frequent malignant tumor of the oral...*3rd November, 2009
Univ.-Klinik fur Mund-, Kiefer- und Gesichtschirurgie, Paracelsus- Hautarzt. 2009 Nov 1. ([DOI Direct Link](#))

- [BAG-1 overexpression attenuates luminal apoptosis in MCF-10A mammary epithelial cells through enhanced RAF-1 activation.](#)

*Although the multi-functional, prosurvival protein, Bcl-2-associated...*3rd November, 2009
Cancer Research Program, Garvan Institute of Medical Research,- Oncogene. 2009 Nov 2. ([DOI Direct Link](#))

BioNews Results for Carcinoma In Situ

- [Breast Cancer Stage Zero Can't be Felt Through Self Exam](#)

First Coast News: Nov 14 2009 4:01AM Matching: carcinoma situ

- [Micropapillary ductal carcinoma in situ of the breast: an inter-institutional study](#)

Modern Pathology: Nov 13 2009 4:57PM Matching: carcinoma situ

- [Excision alone inadequate for high grade DCIS](#)

MedWire News: Nov 13 2009 4:37PM Matching: carcinoma situ

- [MRIs and cancer](#)

Bucks County Courier Times: Nov 12 2009 10:17AM Matching: carcinoma situ

- [Endo Pharmaceuticals and LecTec Settle Patent Dispute](#)

Forbes.com: Nov 11 2009 10:37PM Matching: carcinoma situ

- [Endo Pharmaceuticals and LecTec Settle Patent Dispute](#)

NewsBlaze: Nov 11 2009 10:30PM Matching: carcinoma situ

- [Endo Pharmaceuticals and LecTec Settle Patent Dispute](#)

- PR Newswire via MSN Money: Nov 11 2009 10:03PM Matching: carcinoma situ*
- [Endo Pharmaceuticals and LecTec Settle Patent Dispute](#)
- PR Newswire via MSN Money: Nov 11 2009 10:03PM Matching: carcinoma situ*
- [Endo Pharmaceuticals and LecTec Settle Patent Dispute](#)
- PR Newswire via MSN Money: Nov 11 2009 10:02PM Matching: carcinoma situ*
- [1 in 4 breast cancers 'not threatening'](#)
- ABC Online: Nov 11 2009 2:17AM Matching: carcinoma situ*
- [Breast MRI best for finding mammographically occult cancer](#)
- OncoLink: Nov 10 2009 9:23AM Matching: carcinoma situ*
- [As HRT use declines, atypical ductal hyperplasia rates also fal](#)
- OncoLink: Nov 10 2009 9:23AM Matching: carcinoma situ*
- [Presence of Necrosis in Core Biopsy Predicts Close Margin in Ductal Carcinoma Excision Cases: Presented at ASC](#)
- Doctors Guide: Nov 10 2009 12:10AM Matching: carcinoma situ*
- [DUSA Pharmaceuticals \(DUSA\): Independent Study Utilizing Cyclic Levulan PDT Finds 95 Percent Reduction in New](#)
- BioSpace: Nov 10 2009 6:47PM Matching: carcinoma situ*
- [Sore feet worth the walk for cancer survivor in 3-Day event](#)
- Gainesville Times: Nov 8 2009 9:13AM Matching: carcinoma situ*

Carcinoma In Situ Clinical Trials:



- [Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ \(DCIS\)](#)

Carcinoma In Situ Patents:



- 7557107- [Farnesyl protein transferase inhibitors as antitumor agents](#)
- 7579158- [Cellular retinoic acid binding protein II as a marker for breast cancer](#)
- 7579479- [Substituted acid derivatives useful as antidiabetic and antiobesity agents and method](#)
- 7582287- [Method for treating cervical cancer](#)
- 7582645- [Pyrimidine derivatives for treatment of hyperproliferative disorders](#)
- 7582773- [Substituted phenyl indoles](#)
- 7585505- [Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer](#)
- 7585653- [Oncokinase fusion polypeptides associated with hyperproliferative and related disorders, nucleic acids encoding the same and methods for detecting and identifying the same](#)
- 7585888- [Benzofuran and benzothiophene derivatives useful in the treatment of hyper-proliferative](#)

[disorders](#)

- 7588564- [Apparatus for piezoelectric layer-wise pump and valve for use in local administration of biological response modifiers and therapeutic agents](#)
- 7588767- [Microorganisms for therapy](#)
- 7579152- [SENP1 as a marker of cancer development and target for cancer therapy](#)
- 7575574- [Apparatus for piezoelectric layer-wise pump and valve for use in local administration of biological response modifiers and therapeutic agents](#)
- 7572775- [Method of inhibiting intestinal polyps](#)
- 7557129- [Cyanopyridine derivatives useful in the treatment of cancer and other disorders](#)
- 7557142- [Therapeutic use of methionine to reduce the toxicity of platinum-containing anti-tumor compounds](#)
- 7563444- [Nucleic acid and corresponding protein entitled 213P1F11 useful in treatment and detection of cancer](#)
- 7563791- [Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis](#)
- 7566542- [Use of protein ASC as a marker for breast cancer](#)
- 7566791- [Substituted 3-carbonyl-1h-indol-1yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 \(PAI-1\)](#)
- 7569051- [Apparatus for piezoelectric layer-wise pump and valve for use in local administration of biological response modifiers and therapeutic agents](#)
- 7569384- [Albumin fusion proteins](#)
- 7569568- [Cytokine inhibitors](#)
- 7569573- [Diketo acids with nucleobase scaffolds: anti-HIV replication inhibitors targeted at HIV integrase](#)
- 7588771- [Microorganisms for therapy](#)
- 7588904- [Perinucleolar compartment as a cancer marker](#)
- 7601825- [Nucleic acid and corresponding protein entitled 121P1F1 useful in treatment and detection of cancer](#)
- 7604944- [Oncokine fusion polypeptides associated with hyperproliferative and related disorders, nucleic acids encoding the same and methods for detecting and identifying the same](#)
- 7605139- [DNA cancer vaccines](#)
- 7608259- [Methods of cancer diagnosis and therapy targeted against a cancer stem line](#)
- 7608635- [Pyrazole compounds that modulate HSP90 activity](#)
- 7608696- [IBC-1 \(invasive breast cancer-1\), a putative oncogene amplified in breast cancer](#)
- 7608704- [Secreted proteins](#)
- 7611879- [27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 and 65577 molecules and uses therefor](#)
- 7612172- [Nucleic acids and corresponding proteins entitled 282P1G3 useful in treatment and detection of cancer](#)
- 7615046- [Apparatus and method for the controlled hydrodistention of the urinary bladder](#)
- 7601505- [Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer](#)
- 7601355- [Compositions and methods for altering immune function](#)
- 7599542- [System and method for detection and display of diseases and abnormalities using confidence imaging](#)
- 7589112- [Methylene urea derivatives](#)
- 7592010- [Albumin fusion proteins](#)
- 7592149- [Nucleic acid and corresponding protein entitled 184P1E2 useful in treatment and detection of cancer](#)
- 7592319- [Uses of DNA-PK](#)
- 7592332- [Cytokine inhibitors](#)
- 7592422- [Modified plasminogen activator inhibitor type-1 and methods based thereon](#)
- 7595379- [Antibodies and related molecules that bind to PSCA proteins](#)

- 7595380- [Monoclonal antibodies and methods for their use in the detection of cervical disease](#)
- 7597884- [Hyperglycosylated polypeptide variants and methods of use](#)
- 7598341- [Molecules that selectively home to vasculature of premalignant or malignant lesions of the pancreas and other organs](#)
- 7615379- [Nucleic acid and corresponding protein entitled 193P1E1B useful in treatment and detection of cancer](#)

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

